ClinicalTrials.gg
CompletedNCT01799941PRISM IIUpdated Mar 15, 2017Results posted

Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

A Phase 4 interventional study of Nuedexta (DM 20 mg/Q 10 mg) in Pseudobulbar Affect (PBA), Stroke and Dementia, sponsored by Avanir Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by Avanir Pharmaceuticals (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
367
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,995 studies in Stroke with a site in United States — 395 open to participants now, 492 under way, 17 of them phase 3. Stroke · United States.

Enrollment
180th of 1,621
367 · median 40
Started
2013
with 83 others
Phase 4
43 of 1,995
5 open now
Registered
582nd of 1,995
by date

Among the 1,995 studies in Stroke with a site in United States, this one is the 180th largest by enrollment of the 1,621 interventional ones that give a count, is one of 84 that started in 2013, is one of 43 in phase 4, and was the 582nd registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

395 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:

390 more — sign in →

All 395 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,995 studies in Stroke with a site in United States, or all of them as a file.
02

Study summary

The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with prevalent conditions such as dementia, stroke, and traumatic brain injury (TBI)over a 12 week period.

Read the detailed description

This will be an Open-label, Multicenter, study in patients with PBA and dementia, stroke or TBI. Patients with a clinical diagnosis of PBA and who meet all other inclusion and exclusion criteria will be eligible to participate and receive NUEDEXTA for 12 weeks.

Males and females patients with a minimum age of 18 years, a clinical diagnosis of Pseudobulbar Affect and a documented diagnosis of neurologic disease or brain injury, will be enrolled in this study.

The primary effectiveness endpoint is the mean change in the Center for Neurologic Study-Lability scale (CNS-LS). Secondary objectives include measures to evaluate treatment outcomes.

03

Conditions studied

  • Pseudobulbar Affect (PBA)
  • Stroke
  • Dementia
  • Traumatic Brain Injury (TBI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Center for Neurologic Study-Lability Scale (CNS-LS)score of 13 or greater
  • Clinical diagnosis of Pseudobulbar Affect (PBA)
  • Documentation of Neurologic disease or brain injury

Exclusion criteria

Exclusion Criteria:

  • Unstable neurologic disease
  • Severe dementia
  • Stroke within 3 months
  • Penetrating TBI
  • to Nuedexta
  • Severe Depressive Disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
367 participants (actual)

Study arms

  • Other
    Nuedexta (DM 20 mg/Q 10 mg)

    Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)

    Drug: Nuedexta (DM 20 mg/Q 10 mg)

Interventions

  • DrugNuedexta (DM 20 mg/Q 10 mg)

    Drug page: Dextromethorphan

    Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)

    Also known as: Nuedexta

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 90

    The CNS-LS was a seven-item, self-administered questionnaire, completed by the participant or participant's caregiver that provided a quantitative measure of the perceived frequency and severity of Pseudobulbar Affect (PBA) episodes. It consisted of two subscales measuring labile laughter (four items) and labile crying (three items). Each item was rated on a scale from 1 (applies never) to 5 (applies most of the time). The total score was calculated as the sum of the item values that resulted in a score ranging from 7 (no symptoms) to 35 (maximum symptom severity and frequency). A single continuous variable was created for the reported time point. The change in CNS-LS was calculated as the score from the Day 90 assessment minus the Baseline CNS-LS measure. A negative change represented a decrease in CNS-LS score over time following the baseline assessment indicating a perceived decrease in frequency and severity of PBA episodes.

    Time frame: Day 90 (Final visit)

Secondary outcomes

  1. Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 30

    The CNS-LS was a seven-item, self-administered questionnaire, completed by the participant or participant's caregiver that provided a quantitative measure of the perceived frequency and severity of Pseudobulbar Affect (PBA) episodes. It consisted of two subscales measuring labile laughter (four items) and labile crying (three items). Each item was rated on a scale from 1 (applies never) to 5 (applies most of the time). The total score was calculated as the sum of the item values that resulted in a score ranging from 7 (no symptoms) to 35 (maximum symptom severity and frequency). A single continuous variable was created for the reported time point. The change in CNS-LS was calculated as the score from the Day 30 assessment minus the Baseline CNS-LS measure. A negative change represented a decrease in CNS-LS score over time following the baseline assessment indicating a perceived decrease in frequency and severity of PBA episodes.

    Time frame: Day 30

  2. Mean Pseudobulbar Affect (PBA) Episode Count Per Week by Visit

    PBA episode count was an investigator assessed measure in which the participant/participant's daytime caregiver was asked to identify, count and recall the total episodes of exaggerated/uncontrollable laughing or crying over the previous 7 days (prior to visit) at Baseline (Day 1), Day 30 (Visit 1), and Day 90 (Final visit). The response categories for this question were: 0, 1- 2, 3-5, 6-10, \>10. The original responses from participants were converted to estimate the continuous number of PBA episodes by taking the mid-point of the original response ranges and multiplying that value by 7. Data is presented as mean PBA count per week.

    Time frame: Baseline (Day 1), Day 30 (Visit 1), and Day 90 (Final visit)

  3. Percentage of Participants With PBA Remission

    PBA remission was defined as participants with one or more episodes reported at the baseline (Day 1) visit and zero episodes reported at the Day 30 (Visit 1) or Day 90 (Final visit). Data is reported as percentage of participants with no reported episodes over the previous 7 days (prior to visit) at Day 30 (Visit 1) and Day 90 (Final visit).

    Time frame: Day 30 (Visit 1) and Day 90 (Final visit)

  4. Percentage Change From Baseline in PBA Episode Count Per Week

    The change from the baseline PBA rate was measured using Mixed Effects Poisson Regression Model (adjusted for gender and age \[≤ 65 years\]).

    Time frame: Day 30 (Visit 1) and Day 90 (Final visit)

  5. Percentage of Participants With ≥ 50% Reduction in PBA Episode Count Per Week

    Data is reported as the percentage of participants with ≥ 50% reduction in PBA episode count/week.

    Time frame: Day 30 (Visit 1) and Day 90 (Final visit)

  6. Percentage of Participants With ≥ 75% Reduction in PBA Episode Count Per Week

    Data is reported as the percentage of participants with ≥ 75% reduction in PBA episode count/week.

    Time frame: Day 30 (Visit 1) and Day 90 (Final visit)

  7. Mean Change From Baseline in Quality of Life Visual Analog Scale (QOL-VAS) Score at Day 90

    The QOL-VAS, a participant reported scale of quality of life (QOL) was used to measure the impact of PBA episodes on the participant's QOL over the previous 7 days (prior to visit) at Baseline (Day 1) and Day 90 (Final visit). The assessment was completed by a participant placing a mark on a horizontal line that extends from 0 "not (affected) at all" to 10 "significantly (affected)". The participant's mark was measured and recorded at each time point. The change in QOL-VAS score from baseline to day 90 visit, defined as the day 90 score minus the baseline score, was analyzed. Data is reported as mean QOL-VAS score; a positive change in score represented an increase in participant's quality of life.

    Time frame: Day 90 (Final visit)

  8. Percentage of Participants With Clinical Global Impression-Change (CGI-C) Score at Day 90

    CGI-C, an investigator-assessed scale was used to measure the overall treatment response. CGI-C, a 7-point (1-7) scale was rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data is presented as percentage of participants with CGI-C score at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.

    Time frame: Day 90 (Final visit)

  9. Percentage of Participants With Patient Global Impression-Change (PGI-C) Score at Day 90

    PGI-C, a participant/participant's caregiver-assessed scale was used to measure participant overall treatment response. PGI-C, a 7-point (1-7) scale was rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data is presented as percentage of participants with PGI-C score at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.

    Time frame: Day 90 (Final visit)

  10. Percentage of Participants With Treatment Satisfaction Survey

    The treatment satisfaction survey was a 5 point single question survey that was administered by the site staff to the participant/participant's caregiver. Participants were asked to rate their response to treatment satisfaction as: very dissatisfied, somewhat dissatisfied, neither satisfied nor dissatisfied, somewhat satisfied, and very satisfied. Data is presented as percentage of participants with treatment satisfaction at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.

    Time frame: Day 90 (Final visit)

  11. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AEs (defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) and SAEs (defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening \[ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death\], required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug) were assessed during the study.

    Time frame: From signing of informed consent up to 30 days after receiving the last dose of study drug or up to approximately 120 days

07

Results

Posted Mar 15, 2017

Participant flow

Participant flow — Overall Study
MilestoneDextromethorphan Hydrobromide 20 mg + Quinidine Sulfate 10 mg
Started367
Completed271
Not completed96
Withdrew: Adverse event34
Withdrew: Withdrawal by subject21
Withdrew: Death2
Withdrew: Investigator decision4
Withdrew: Lack of efficacy3
Withdrew: Lost to follow-up17
Withdrew: Other15

Outcome measures

PrimaryMean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 90

The CNS-LS was a seven-item, self-administered questionnaire, completed by the participant or participant's caregiver that provided a quantitative measure of the perceived frequency and severity of Pseudobulbar Affect (PBA) episodes. It consisted of two subscales measuring labile laughter (four items) and labile crying (three items). Each item was rated on a scale from 1 (applies never) to 5 (applies most of the time). The total score was calculated as the sum of the item values that resulted in a score ranging from 7 (no symptoms) to 35 (maximum symptom severity and frequency). A single continuous variable was created for the reported time point. The change in CNS-LS was calculated as the score from the Day 90 assessment minus the Baseline CNS-LS measure. A negative change represented a decrease in CNS-LS score over time following the baseline assessment indicating a perceived decrease in frequency and severity of PBA episodes.

Time frame:
Day 90 (Final visit)
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 90
Units on a scaleOverallDementiaStrokeTraumatic Brain Injury
Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 90-7.69 ± 6.07-7.22 ± 6.04-7.59 ± 6.67-8.54 ± 5.18
Statistical analysis
  • Overall · One sample t-test · p = <0.0001
  • Dementia · one-sample t-test · p = <0.0001
  • Stroke · One-sample t-test · p = <0.0001
  • Traumatic Brain Injury · One-sample t-test · p = <0.0001
  • Dementia vs Stroke · Analysis of covariance (ancova): 0.04 · 95% CI -1.37 to 1.45A positive estimate indicates a smaller change in the first group. Observations used =261.
  • Stroke vs Traumatic Brain Injury · Ancova: 1.11 · 95% CI -0.46 to 2.68A positive estimate indicates a smaller change in the first group. Observations used =261.
  • Dementia vs Traumatic Brain Injury · Ancova: 1.15 · 95% CI -0.39 to 2.69A positive estimate indicates a smaller change in the first group. Observations used =261.
SecondaryMean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 30

The CNS-LS was a seven-item, self-administered questionnaire, completed by the participant or participant's caregiver that provided a quantitative measure of the perceived frequency and severity of Pseudobulbar Affect (PBA) episodes. It consisted of two subscales measuring labile laughter (four items) and labile crying (three items). Each item was rated on a scale from 1 (applies never) to 5 (applies most of the time). The total score was calculated as the sum of the item values that resulted in a score ranging from 7 (no symptoms) to 35 (maximum symptom severity and frequency). A single continuous variable was created for the reported time point. The change in CNS-LS was calculated as the score from the Day 30 assessment minus the Baseline CNS-LS measure. A negative change represented a decrease in CNS-LS score over time following the baseline assessment indicating a perceived decrease in frequency and severity of PBA episodes.

Time frame:
Day 30
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 30
Units on a scaleOverallDementiaStrokeTraumatic Brain Injury
Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 30-5.43 ± 5.52-4.60 ± 5.08-6.17 ± 6.12-5.58 ± 5.21
Statistical analysis
  • Overall · One-sample t-test · p = <0.0001
  • Dementia · One-sample t-test · p = <0.0001
  • Stroke · One-sample t-test · p = <0.0001
  • Traumatic Brain Injury · One-sample t-test · p = <0.0001
SecondaryMean Pseudobulbar Affect (PBA) Episode Count Per Week by Visit

PBA episode count was an investigator assessed measure in which the participant/participant's daytime caregiver was asked to identify, count and recall the total episodes of exaggerated/uncontrollable laughing or crying over the previous 7 days (prior to visit) at Baseline (Day 1), Day 30 (Visit 1), and Day 90 (Final visit). The response categories for this question were: 0, 1- 2, 3-5, 6-10, \>10. The original responses from participants were converted to estimate the continuous number of PBA episodes by taking the mid-point of the original response ranges and multiplying that value by 7. Data is presented as mean PBA count per week.

Time frame:
Baseline (Day 1), Day 30 (Visit 1), and Day 90 (Final visit)
Reported as:
Mean · Count/week
Mean Pseudobulbar Affect (PBA) Episode Count Per Week by Visit
Count/weekOverallDementiaStrokeTraumatic Brain Injury
Baseline21.33 ± 24.9725.68 ± 23.0619.62 ± 29.6217.94 ± 20.31
Day 30 (n= 296, 108, 102, 86)9.10 ± 14.2912.85 ± 16.806.95 ± 11.836.94 ± 12.60
Day 90 (n= 260, 102, 92, 66)6.23 ± 11.458.41 ± 14.265.26 ± 9.604.20 ± 8.02
Statistical analysis
  • Overall · One-sample t-test · p = <0.0001
  • Overall · One-sample t-test · p = <0.0001
  • Dementia · One-sample t-test · p = <0.0001
  • Dementia · One-sample t-test · p = <0.0001
  • Stroke · One-sample t-test · p = <0.0001
  • Stroke · One-sample t-test · p = <0.0001
  • Traumatic Brain Injury · One-sample t-test · p = <0.0001
  • Traumatic Brain Injury · One-sample t-test · p = <0.0001
SecondaryPercentage of Participants With PBA Remission

PBA remission was defined as participants with one or more episodes reported at the baseline (Day 1) visit and zero episodes reported at the Day 30 (Visit 1) or Day 90 (Final visit). Data is reported as percentage of participants with no reported episodes over the previous 7 days (prior to visit) at Day 30 (Visit 1) and Day 90 (Final visit).

Time frame:
Day 30 (Visit 1) and Day 90 (Final visit)
Reported as:
Number · Percentage of participants
Percentage of Participants With PBA Remission
Percentage of participantsOverallDementiaStrokeTraumatic Brain Injury
Day 30 (n= 296, 108, 102, 86)20.313.022.526.7
Day 90 (n= 260, 102, 92, 66)35.431.434.842.4
SecondaryPercentage Change From Baseline in PBA Episode Count Per Week

The change from the baseline PBA rate was measured using Mixed Effects Poisson Regression Model (adjusted for gender and age \[≤ 65 years\]).

Time frame:
Day 30 (Visit 1) and Day 90 (Final visit)
Reported as:
Mean · percent change
Percentage Change From Baseline in PBA Episode Count Per Week
percent changeOverallDementiaStrokeTraumatic Brain Injury
Day 30 (n= 296, 108, 102, 86)-57.5 (-59.3 to -55.5)-50.0 (-53.1 to -46.6)-64.9 (-67.7 to -61.7)-61.3 (-64.8 to -57.7)
Day 90 (n=260, 102, 92, 66)-72.3 (-73.8 to -70.8)-67.7 (-70.1 to -65.1)-74.5 (-76.9 to -71.8)-78.5 (-81.2 to -75.7)
Statistical analysis
  • Overall · Mixed Effects Poisson Regreesion Model · p = <0.0001 · Incidence rate ratio: 0.425 · 95% CI 0.407 to 0.445Number of observations = 854, Number of participants = 298
  • Overall · Mixed Effects Poisson Regression Model · p = <0.0001 · Incidence rate ratio: 0.277 · 95% CI 0.262 to 0.293Number of observations = 854, Number of participants = 298
  • Dementia · Mixed Effects Poisson Regression Model · p = <0.0001 · Incidence rate ratio: 0.500 · 95% CI 0.469 to 0.534Number of observations = 318, Number of participants = 108
  • Dementia · Mixed Effects Poisson Regression Model · p = <0.0001 · Incidence rate ratio: 0.323 · 95% CI 0.299 to 0.349Number of observations = 318, Number of participants = 108
  • Stroke · Mixed Effects Poisson Regression Model · p = <0.0001 · Incidence rate ratio: 0.351 · 95% CI 0.323 to 0.383Number of observations = 297, Number of participants = 103
  • Stroke · Mixed Effects Poisson Regression Model · p = <0.0001 · Incidence rate ratio: 0.255 · 95% CI 0.231 to 0.282Number of observations = 297, Number of participants = 103
  • Traumatic Brain Injury · Mixed Effects Poisson Regression Model · p = <0.0001 · Incidence rate ratio: 0.387 · 95% CI 0.352 to 0.425Number of observations = 239, Number of participants = 87
  • Traumatic Brain Injury · Mixed Effects Poisson Regression Model · p = <0.0001 · Incidence rate ratio: 0.215 · 95% CI 0.189 to 0.245Number of observations = 239, Number of participants = 87
SecondaryPercentage of Participants With ≥ 50% Reduction in PBA Episode Count Per Week

Data is reported as the percentage of participants with ≥ 50% reduction in PBA episode count/week.

Time frame:
Day 30 (Visit 1) and Day 90 (Final visit)
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥ 50% Reduction in PBA Episode Count Per Week
Percentage of participantsOverallDementiaStrokeTraumatic Brain Injury
Day 30 (n= 289, 107, 100, 82)63.758.965.068.3
Day 90 (n= 254, 101, 90, 63)78.076.276.782.5
SecondaryPercentage of Participants With ≥ 75% Reduction in PBA Episode Count Per Week

Data is reported as the percentage of participants with ≥ 75% reduction in PBA episode count/week.

Time frame:
Day 30 (Visit 1) and Day 90 (Final visit)
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥ 75% Reduction in PBA Episode Count Per Week
Percentage of participantsOverallDementiaStrokeTraumatic Brain Injury
Day 30 (n= 289, 107, 100, 82)42.233.642.053.7
Day 90 (n= 254, 101, 90, 63)57.157.447.869.8
SecondaryMean Change From Baseline in Quality of Life Visual Analog Scale (QOL-VAS) Score at Day 90

The QOL-VAS, a participant reported scale of quality of life (QOL) was used to measure the impact of PBA episodes on the participant's QOL over the previous 7 days (prior to visit) at Baseline (Day 1) and Day 90 (Final visit). The assessment was completed by a participant placing a mark on a horizontal line that extends from 0 "not (affected) at all" to 10 "significantly (affected)". The participant's mark was measured and recorded at each time point. The change in QOL-VAS score from baseline to day 90 visit, defined as the day 90 score minus the baseline score, was analyzed. Data is reported as mean QOL-VAS score; a positive change in score represented an increase in participant's quality of life.

Time frame:
Day 90 (Final visit)
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Quality of Life Visual Analog Scale (QOL-VAS) Score at Day 90
Units on a scaleOverallDementiaStrokeTraumatic Brain Injury
Mean Change From Baseline in Quality of Life Visual Analog Scale (QOL-VAS) Score at Day 90-3.13 ± 3.21-3.20 ± 2.98-2.66 ± 3.35-3.67 ± 3.29
Statistical analysis
  • Overall · One-sample t-test · p = <0.0001
  • Dementia · One-sample t-test · p = <0.0001
  • Stroke · One-sample t-test · p = <0.0001
  • Traumatic Brain Injury · One-sample t-test · p = <0.0001
SecondaryPercentage of Participants With Clinical Global Impression-Change (CGI-C) Score at Day 90

CGI-C, an investigator-assessed scale was used to measure the overall treatment response. CGI-C, a 7-point (1-7) scale was rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data is presented as percentage of participants with CGI-C score at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.

Time frame:
Day 90 (Final visit)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Global Impression-Change (CGI-C) Score at Day 90
Percentage of participantsOverallDementiaStrokeTraumatic Brain Injury
Very much improved33.730.433.039.7
Much improved42.947.141.838.2
Minimally improved13.413.714.311.8
No change8.88.87.710.3
Minimally worse0.80.02.20.0
Much worse0.40.01.10.0
Veru much worse0.00.00.00.0
SecondaryPercentage of Participants With Patient Global Impression-Change (PGI-C) Score at Day 90

PGI-C, a participant/participant's caregiver-assessed scale was used to measure participant overall treatment response. PGI-C, a 7-point (1-7) scale was rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data is presented as percentage of participants with PGI-C score at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.

Time frame:
Day 90 (Final visit)
Reported as:
Number · Percentage of participants
Percentage of Participants With Patient Global Impression-Change (PGI-C) Score at Day 90
Percentage of participantsOverallDementiaStrokeTraumatic Brain Injury
Very much improved32.628.433.737.3
Much improved39.848.033.735.8
Minimally improved18.814.721.720.9
No change8.07.810.94.5
Minimally worse0.41.00.00.0
Much worse0.40.00.01.5
Veru much worse0.00.00.00.0
SecondaryPercentage of Participants With Treatment Satisfaction Survey

The treatment satisfaction survey was a 5 point single question survey that was administered by the site staff to the participant/participant's caregiver. Participants were asked to rate their response to treatment satisfaction as: very dissatisfied, somewhat dissatisfied, neither satisfied nor dissatisfied, somewhat satisfied, and very satisfied. Data is presented as percentage of participants with treatment satisfaction at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.

Time frame:
Day 90 (Final visit)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Satisfaction Survey
Percentage of participantsOverallDementiaStrokeTraumatic Brain Injury
Very dissatisfied7.74.912.06.0
Somewhat dissatisfied5.46.95.43.0
Neither satisfied nor dissatisfied11.513.78.711.9
Somewhat satisfied28.021.631.532.8
Very satisfied47.552.942.446.3
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AEs (defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) and SAEs (defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening \[ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death\], required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug) were assessed during the study.

Time frame:
From signing of informed consent up to 30 days after receiving the last dose of study drug or up to approximately 120 days
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsOverallDementiaStrokeTraumatic Brain Injury
AEs132494043
SAEs231454

Adverse events

Collected over From signing of informed consent up to 30 days after receiving the last dose of study drug or up to approximately 120 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall—23/367 (6.3%)35/367 (9.5%)
Dementia—14/134 (10.4%)15/134 (11.2%)
Stroke—5/113 (4.4%)9/113 (8%)
Traumatic Brain Injury—4/120 (3.3%)11/120 (9.2%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventOverallDementiaStrokeTraumatic Brain Injury
Urinary tract infectionInfections and infestations3/3671/1340/1132/120
Non-cardiac chest painGeneral disorders1/3670/1341/1130/120
PneumoniaInfections and infestations1/3670/1341/1130/120
Facial bones fractureInjury, poisoning and procedural complications1/3670/1341/1130/120
FallInjury, poisoning and procedural complications2/3671/1341/1130/120
Carotid artery stenosisNervous system disorders1/3670/1341/1130/120
Transient ischaemic attackNervous system disorders1/3670/1341/1130/120
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/3670/1341/1130/120
Myocardial infarctionCardiac disorders1/3670/1340/1131/120
Prostate infectionInfections and infestations1/3670/1340/1131/120
Most frequent other events
Most frequent other events
EventOverallDementiaStrokeTraumatic Brain Injury
DiarrhoeaGastrointestinal disorders20/3675/1345/11310/120
HeadacheNervous system disorders15/36710/1344/1131/120

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dextromethorphan Hydrobromide 20 mg + Quinidine Sulfate 10 mg
<=18 years0
Between 18 and 65 years215
>=65 years152
Sex: Female, Male
Sex: Female, Male(Participants)Dextromethorphan Hydrobromide 20 mg + Quinidine Sulfate 10 mg
Female202
Male165
08

Study locations

1 site
  • Pensacola, Florida 32503, United States
09

References and documents

Publications

  • Hammond FM, Sauve W, Ledon F, Davis C, Formella AE. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study. PM R. 2018 Oct;10(10):993-1003. doi: 10.1016/j.pmrj.2018.02.010. Epub 2018 Feb 23. PubMed 29477412 ↗
  • Hammond FM, Alexander DN, Cutler AJ, D'Amico S, Doody RS, Sauve W, Zorowitz RD, Davis CS, Shin P, Ledon F, Yonan C, Formella AE, Siffert J. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurol. 2016 Jun 9;16:89. doi: 10.1186/s12883-016-0609-0. Erratum In: BMC Neurol. 2016 Sep 2;16(1):160. doi: 10.1186/s12883-016-0679-z. PubMed 27276999 ↗
  • Doody RS, D'Amico S, Cutler AJ, Davis CS, Shin P, Ledon F, Yonan C, Siffert J. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. CNS Spectr. 2016 Dec;21(6):450-459. doi: 10.1017/S1092852915000620. Epub 2015 Oct 16. PubMed 26471212 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2013
First posted
Feb 27, 2013
Start
Feb 2013
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Mar 15, 2017
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01799941
Responsible party
Sponsor
First posted
Feb 27, 2013
Start date
Feb 2013
Primary completion
May 2015
Completion
May 2015
Results posted
Mar 15, 2017
Last update
Mar 15, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan

Start the discussion